Search Results
Your search for ,sIX matches 2810 pages
Showing 151 - 200Advanced-Stage Classical Hodgkin Lymphoma
Classical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and...
Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC
The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, the Pulmonary Pathology Society, the Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations on the use of certain...
Immunotherapy Resistance and Response to Adoptive Therapy in Patients With Metastatic Uveal Melanoma
Researchers may have uncovered the mechanisms behind conventional immunotherapy resistance as well as the efficacy of adoptive therapy in metastatic uveal melanoma, according to a recent study published by Leonard-Murali et al in Nature Communications. The findings demonstrated the potential to...
HER2-Positive Early Breast Cancer: PET-Based, pCR-Adapted Strategy
In the phase II PHERGain trial reported in The Lancet, Pérez-García et al found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive disease–free survival results in patients with HER2-positive early...
Exploring Geriatric Assessment Effectiveness: Insights From the 2023 International Society of Geriatric Oncology Conference
Geriatric assessment has emerged as a pivotal tool in optimizing cancer care for older patients, aiming to mitigate treatment toxicity, enhance treatment adherence, and improve quality of life. The recommended areas for evaluation in a geriatric assessment focus on identifying health issues that...
Newly Diagnosed Locally Advanced HNSCC: Adding Pembrolizumab to Concurrent Chemoradiotherapy
As reported in The Lancet Oncology by Jean-Pascal Machiels, MD, and colleagues, the phase III KEYNOTE-412 trial showed no significant improvement in event-free survival with the addition of pembrolizumab to concurrent chemoradiotherapy in newly diagnosed patients with high-risk locally advanced...
Biologic Drug-Device Combination Immunotherapy in Metastatic Prostate Cancer
SYNC-T—an investigational therapy that combines a device-induced vaccination at the tumor site with an intratumoral infusion of a multitarget biologic drug—led to numerous clinical responses in patients with metastatic castration-resistant prostate cancer, according to results reported at the...
Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit
An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer,...
Advanced Pancreatic Cancer: Oncolytic Virus–Based Immunostimulatory Gene Therapy Plus Chemotherapy
In a single-center phase I/II study (LOKON001) reported in The Lancet Oncology, Musher et al found that treatment with an oncolytic virus–based immunostimulatory gene therapy (LOAd703) plus chemotherapy was feasible and safe in patients with unresectable or metastatic pancreatic ductal...
Model for Predicting Outcomes After Sentinel Lymph Node Biopsy in Melanoma
In a study reported in The Lancet Oncology, Stassen et al developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma. Study Details The study involved a development cohort of 4,071 patients aged > 13...
Inotuzumab Ozogamicin for Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, inotuzumab ozogamicin (Besponsa) was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting Efficacy Data Approval was based on findings in the ITCC-059 trial (ClinicalTrials.gov...
Enfortumab Vedotin Plus Pembrolizumab Yields Benefit in Key Subgroups With Advanced Urothelial Cancer
The combination of the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab achieved favorable rates of progression-free survival, overall survival, and objective responses compared with chemotherapy among key subgroups of patients with previously...
Previously Untreated Advanced Urothelial Cancer: Antibody-Drug Conjugate Plus PD-1 Inhibitor
As reported in The New England Journal of Medicine by Thomas Powles, MD, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody-drug conjugate enfortumab vedotin-ejfv and the PD-1 inhibitor pembrolizumab improved progression-free and overall survival vs...
Novel Dual-Target CAR T-Cell Therapy for Recurrent Glioblastoma
Targeting two brain tumor–associated proteins with chimeric antigen receptor (CAR) T-cell therapy may reduce solid tumor growth in patients with recurrent glioblastoma, according to results from a phase I trial published by Bagley et al in Nature Medicine. The findings suggest that the new...
Newly Diagnosed Multiple Myeloma
“Ask yourself at every moment, ‘Is this necessary?’” —Marcus Aurelius To complement The ASCO Post’s extensive coverage of the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two important abstracts selected from the meeting proceedings focusing on induction and...
Esophageal Squamous Cell Cancer: Overall Survival Improved With Tiragolumab and Atezolizumab Plus Chemotherapy
For patients with treatment-naive, locally advanced or metastatic esophageal squamous cell carcinoma, the addition of two checkpoint inhibitors to chemotherapy significantly improved not only progression-free survival but also overall survival, in the randomized, phase III SKYSCRAPER-08 trial...
FDA Approves Nivolumab in Combination With Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma
On March 6, the U.S. Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opdivo) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. CheckMate 901 Efficacy was evaluated in CheckMate ...
Novel CD123-Targeting Antibody-Drug Conjugate in Relapsed or Refractory AML
In a phase I/II study reported in The Lancet Oncology, Naval Daver, MD, and colleagues found that pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, showed activity in patients with CD123-positive relapsed or refractory acute myeloid leukemia (AML). Study Details...
Online Genetic Education Programs May Spur Testing for Patients at Risk for Cancer
Researchers have demonstrated that an online genetic education program may encourage patients with a family history of cancer to undertake genetic testing, according to a recent study published by Rodriguez et al in Gastroenterology. Background Although research has shown that an inherited...
Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of Ro-CHOP Trial
As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously...
Gene Signature May Predict Response to Combination Therapy in Patients With NSCLC
Researchers have identified a set of 140 genes that may help predict disease-free survival in patients with non–small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation, according to a recent study published by Altorki et al in Cell Reports Medicine. The...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Exploring the Role of Intravenous Mistletoe Extract in Treating Metastatic Solid Tumors
Guest Editor’s Note: The use of mistletoe extract to support systemic therapy and improve quality of life for patients with cancer, though common, remains controversial. Promising results have been reported, but largely in trials that were not placebo-controlled nor properly randomized. In this...
IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?
Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...
SBRT vs Conventional External-Beam Radiotherapy for Painful Bone Metastases
In a systematic review and meta-analysis reported in JAMA Network Open, Bindels et al found no difference in overall pain response rates between stereotactic body radiotherapy (SBRT) and conventional external-beam radiotherapy (cEBRT) in terms of relief of pain for patients with painful bone...
Annual Report to the Nation, Part 2: New Cancer Diagnoses Fell Abruptly Early in the COVID-19 Pandemic
New diagnoses of six major cancer types in the United States fell abruptly in early 2020, coinciding with the start of the COVID-19 pandemic, according to findings from part 2 of the latest Annual Report to the Nation on the Status of Cancer.1 The volume of pathology reports also declined sharply...
Long-Term Follow-up of the Anthracyclines in Early Breast Cancer (ABC) Trials
As reported in the Journal of Clinical Oncology by Charles E. Geyer Jr, MD, and colleagues, long-term follow-up of the ABC trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]) showed that noninferiority of adjuvant nonanthracycline therapy was not demonstrated vs...
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
On February 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for adult patients with unresectable or metastatic melanoma who were previously treated with a PD-1 blocking antibody, or, if they have...
Study Finds Four-Drug Targeted Treatment Reduces Chemotherapy Requirement for Some in Large B-Cell Lymphoma
A four-drug targeted therapy regimen proved safe and effective as the first-line treatment of diffuse large B-cell lymphoma (DLBCL), achieving a 100% response rate after four cycles, researchers from The University of Texas MD Anderson Cancer Center, Houston, reported at the 2023 American Society...
Highlights From the 2023 ASH Annual Meeting & Exposition
Hordes of classical and malignant hematologists returned to the tranquil city of San Diego for the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition this past December. The packed agenda lit the Gaslight District up with neuron-searing data, creating an environment for...
Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest
Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...
MRD Markers and Outcomes in Patients With MDS After Stem Cell Transplant
In a Scandinavian study reported in the Journal of Clinical Oncology, Tobiasson et al found that individual-patient measurable residual disease (MRD) could be assessed by next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) to predict outcomes in patients with...
Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel
As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...
Triplet Without or With Ipilimumab in Kidney Transplant Recipients With Advanced Cutaneous Cancers
In a small phase I/II trial reported in the Journal of Clinical Oncology, Schenk et al found that treatment with tacrolimus, prednisone, and nivolumab without or with ipilimumab produced few responses in kidney transplant recipients with advanced skin cancers, with treatment-related allograft loss...
AMBASSADOR: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma
Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized...
OVHIPEC-1 Trial: Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Improves Survival in Advanced Ovarian Cancer
The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...
Canadian Study Shows Myeloma Outcomes in the Real World May Be Worse Than Clinical Trials Suggest
Patients with multiple myeloma treated in the “real world” had worse outcomes than patients who received the same treatment on clinical trials, according to research presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition.1 In a pooled analysis of clinical trial...
Personalized Ibrutinib-Plus-Venetoclax Therapy: New Treatment Standard for Chronic Lymphocytic Leukemia?
A time-limited approach based on measurable residual disease (MRD) response could signal a potential paradigm shift for front-line treatment of chronic lymphocytic leukemia (CLL), according to data presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition1 and...
Use of Enzalutamide in Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence
On November 16, 2023, the androgen receptor inhibitor enzalutamide was approved for use in patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.1 Supporting Efficacy Data Approval was based on the EMBARK trial (ClinicalTrials.gov...
First-Line Nivolumab Plus Ipilimumab Shows Benefit in Metastatic Colorectal Cancer Subset
In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer derived significant benefit from an immunotherapy doublet of nivolumab plus ipilimumab in the first-line setting, which...
Prevalence of Substance Use Disorders Among U.S. Adult Cancer Survivors
In a study reported in JAMA Oncology, Jones et al found a prevalence of active substance use disorders of 3.8% among U.S. adult survivors of solid tumor cancers, with higher rates among those with head/neck, esophageal/gastric, and cervical cancers as well as melanoma. Study Details The study used...
Normal Risk Ovarian Screening Study: Long-Term Update
As reported in the Journal of Clinical Oncology by Han et al, the 21-year update of the Normal Risk Ovarian Screening Study (NROSS) has shown that the NROSS screening strategy remains effective for the detection of ovarian cancer and detection at early disease stages. Study Details The NROSS...
Addition of Avasopasem to SBRT in Localized Pancreatic Cancer
Editor’s note: On publication of this news item reporting on a paper by Dr. Cullen Taniguchi and colleagues, The ASCO Post learned of Dr. Taniguchi’s untimely death on November 14, 2023. To read about the remarkable life and career of Dr. Taniguchi, please visit gsbs.uth.edu. In a phase Ib/II trial ...
Long-Term Follow-up Supports Postneoadjuvant T-DM1 Over Trastuzumab in Early, High-Risk, HER2-Positive Breast Cancer
At a median follow-up of 8.4 years, adjuvant use of ado-trastuzumab emtansine (T-DM1) continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy. These ...
Use of Carvedilol to Help Prevent Heart Failure in Childhood Cancer Survivors
Researchers discovered that the blood vessel–relaxing agent carvedilol may be safe and effective at reducing the risk of heart failure in childhood cancer survivors, according to a recent study published by Armenian et al in The Lancet Oncology. These findings indicate carvedilol may improve...
Atezolizumab Plus Carboplatin in Metastatic Triple-Negative Breast Cancer
Researchers have evaluated the efficacy of atezolizumab in combination with carboplatin in patients with triple-negative breast cancer, according to a recent study published by Lehmann et al in JAMA Oncology. The new findings may help researchers better understand biomarkers of immunotherapy...
Muscle-Invasive Bladder Cancer: 5-Year Survival With dd-MVAC
As reported in The Lancet Oncology by Pfister et al, a 5-year analysis of the French phase III VESPER trial showed no improvement in overall survival with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) vs gemcitabine and cisplatin (GC) in the total perioperative...
Addition of SBRT to Standard-of-Care Systemic Therapy in Oligoprogressive Disease
In the phase II CURB trial reported in The Lancet, Chiaojung Jillian Tsai, MD, PhD, and colleagues found that the addition of stereotactic body radiotherapy (SBRT) to standard-of-care systemic therapy was associated with improved progression-free survival in the total study population of patients...
OVHIPEC-1 Trial: Hyperthermic Intraperitoneal Chemotherapy Plus Interval Cytoreductive Surgery Improves Survival in Advanced Ovarian Cancer
The final survival analysis of the Dutch-Belgian phase III OVHIPEC-1 trial showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery was associated with maintained progression-free and overall survival benefits at 10 years in women with advanced ...
